Physician profile
Avery A Jeffers
NPI 1386083764
$1,911.58
in general payments reported to CMS, 2019-2025
24 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.67 · 2020: $120 · 2021: $324 · 2022: $396 · 2023: $274 · 2024: $348 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $955.83 | 2021-2025 | |
| Novo Nordisk INC | $213.00 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.74 | 2020-2025 | Xifaxan |
| Lilly USA, LLC | $93.16 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $59.84 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.47 | 2022 | |
| Phathom Pharmaceuticals, INC. | $45.91 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $41.75 | 2021 | |
| Abbott Laboratories | $41.45 | 2021-2022 | |
| Allergan, INC. | $35.57 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.08 | 2021-2023 | Trintellix |
| Genentech USA, INC. | $28.33 | 2020-2022 | |
| Pfizer INC. | $27.34 | 2021-2023 | |
| Amarin Pharma, INC. | $25.16 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.87 | 2024 | Gvoke Hypopen |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.38 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $18.56 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $18.29 | 2023 | |
| Lundbeck LLC | $16.41 | 2025 | Rexulti |
| Medtronic, INC. | $15.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.00 | 2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $12.65 | 2021 | |
| Innocoll Pharmaceuticals Limited | $12.56 | 2022 | |
| Merck Sharp & Dohme LLC | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avery Jeffers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.